NCT00499187|Completed
Fanconi Syndrome Due to ARVs in HIV-Infected Persons
A Preliminary Evaluation of Fanconi Syndrome Due to Antiretroviral Therapies in HIV-Infected Persons
Loading search results
A Preliminary Evaluation of Fanconi Syndrome Due to Antiretroviral Therapies in HIV-Infected Persons
Sponsor study identifier
observational
56
2 countries
13
Study Start
September 2007
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
March 2011
Actual (reported)Study Completion
March 2011
Actual (reported)Cross-sectional cohort study of participants with HIV with or without protocol-defined Fanconi syndrome (confirmed creatinine clearance \[CLcr\] decline and evidence of proximal tubulopathy).
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
March 2011
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
July 9, 2007
Actual (reported)July 11, 2007
Actual (reported)September 2007
Date type not reportedThis date has not been verified as actual or estimated.
March 2011
Actual (reported)March 2011
Actual (reported)Time to TDF discontinuation after diagnosis of Fanconi syndrome
Up to 48 weeks
Time to confirmed resolution of Fanconi syndrome
Up to 48 weeks
This cohort enrolled participants with evidence of protocol-defined Fanconi syndrome (confirmed creatinine clearance decline and evidence of proximal tubulopathy).
This cohort enrolled participants with no evidence of protocol-defined Fanconi syndrome.
A single whole blood sample was collected for genomic analysis.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
HIV infected subjects with protocol defined Fanconi Syndrome
Los Angeles, California, 90059, United States
Denver, Colorado, 80220, United States
Miami, Florida, 33136, United States
Atlanta, Georgia, 30308, United States
University of Indiana
Indianapolis, Indiana, 46202, United States
Baltimore, Maryland, 21205, United States
Detroit, Michigan, 48202, United States
Whole blood
John Flaherty, PharmD
Gilead Sciences
56 participants (actual enrollment reported by the registry).
First Submitted
July 9, 2007
First Posted
July 11, 2007
Study Start
September 2007
Date type not reportedThis date has not been verified as actual or estimated.
Effects of Bortezomib-Based Therapy on Cellular Immunity and Response to DC/Myeloma Fusion Vaccines in Vitro
Contact the study team to confirm eligibility.
New York, New York, 10029, United States
Cleveland, Ohio, 44106, United States
Houston, Texas, 77004, United States
Vancouver, British Columbia, V6Z 1Y6, Canada
Toronto, Ontario, M4N 3M5, Canada
Montreal, Quebec, H2L 2W5, Canada
Primary Completion
March 2011
Actual (reported)Study Completion
March 2011
Actual (reported)Last Updated
March 17, 2014
Record last verified: 2014-03
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: